The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Open accessPublished version of a preprint
Abstract
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial–mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC. Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404–15. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
From Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? (2016) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Rociletinib (CO-1686; Clovis Oncology) is a small-molecule, orally available, mutant-selective covalent inhibitor of commonly mutated forms of EGFR, including exon 19 deletions, L858R, and T790M, but not exon 20 insertions.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (XegafriTM, CO-1686) (65), developed by Clovis Oncology, is a specific mutant agent for the treatment of NSCLC, belonging to the third-generation EGFR TKIs.190,191”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [190]
In the citing paper
“Additionally, covalent inhibitors can exhibit high selectivity for proteins with non-conserved residues between variant forms or protein family members [41].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [41]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Indeed, pre-clinical reports have suggested that “third generation” agents can induce switching to multiple signaling mechanisms that bypass EGFR dependency such as ERK and AKT pathways (35, 61, 62).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Preclinical studies have confirmed that rociletinib has minimal activity against wild-type EGFR.7”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“In xenograft models with EGFR-activating mutations alone or combined with T790M resistance mutations, rociletinib resulted in durable tumor shrinkage, 7 which was most marked when plasma concentrations were maintained at more than 200 ng per milliliter across the dosing interval.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Indeed, it seems that EGFR monoclonal antibodies 60 and EGFR WT kinase sparing covalent T790M selective TKIs 61 are ineffective in typical EGFR exon 20 insertion mutants.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [61]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“Additional pre-clinical studies have also identified activation of MAPK signaling and IGF1R signaling as well as epithelial to mesenchymal (EMT) transition as potential resistance mechanisms to WZ4002 and CO-1686 (15, 19, 20).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“In vitro and in vivo studies demonstrated that Rociletinib irreversibly and selectively inhibits mutant EGFR, including T790M mutation, with minimal activity against wild type EGFR, suggesting that drug tolerability to this agent may be superior to first and second generation EGFR inhibitors”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [85]
In the citing paper
“Osimertinib and rociletinib are 3rd generation EGFR-TKIs, both of which are reported to be effective in lung cancer cells harboring EGFR T790M in preclinical models [30, 32].”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Patients with the most common EGFR mutations (L858R mutation in exon 21 and delE746-A750 deletions in exon 19) typically have good responses to therapy with first-generation reversible EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib (3-5).”
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“second site EGFR point mutation that results in the substitution of threonine with methionine at amino acid position 790 (T790M;(7-10)).”
BackgroundSelf-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citation
Cited by
Sorted by citations
Items 601–686 of 686
Cuan, X., Wang, J., Zhao, Y., Yan, J., Sheng, J., & Huang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020629
Focused ultrasound enhances lazertinib delivery in an EGFR-mutant brain metastasis rat modelPreprint
Kong, C., Oh, S., Chung, Y. S., Han, S., & Chang, W. S. (2025) · Research Square · doi:10.21203/rs.3.rs-7181025/v1
Response prediction of radiotherapy in lung cancer patients using multimodal data
Duan, X., Gong, Y., Wei, L., Lu, C., Song, X., & Li, Y. (2025) · Journal of Applied Clinical Medical Physics · doi:10.1002/acm2.70277
Hu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26585745
Self-citationGong, H., Li, Y., Yuan, Y., Li, W., Zhang, H., Zhang, Z., Shi, R., Liu, M., Liu, C., Chen, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336255
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Feng, F., Chen, H., Song, T., Song, P., Bai, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12299693
Ibrahim, M. T., Uzairu, A., Shallangwa, G. A., & Uba, S. (2020) · Figshare · doi:10.6084/m9.figshare.13257669
Gong, H., Li, Y., Yuan, Y., Li, W., Zhang, H., Zhang, Z., Shi, R., Liu, M., Liu, C., Chen, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336258
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Feng, F., Chen, H., Song, T., Song, P., Bai, G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12299687
Gong, H., Li, Y., Yuan, Y., Li, W., Zhang, H., Zhang, Z., Shi, R., Liu, M., Liu, C., Chen, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336261
Hu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26585751
Self-citationHu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26585748
Self-citationDarash‐Yahana, M., Soudah, N., Baskin, A., Levy-Saar, I., Levitzki, A., & Engelberg, D. (2026) · iScience · doi:10.1016/j.isci.2026.116629
Kang, H., Ahn, S., Jung, E., & Shin, S. Y. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130733
Comparison of Cell Line-Derived and Patient-Derived Xenograft Technologies in Oncology (Review)
Gantsova, E. A., Arutyunyan, I. V., Perevyazkina, G. D., Gordon, К. В., & Fatkhudinov, T. (2026) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-026-06735-5
Dahab, M. A., Ashoub, A. F., Ali, R. A., Sallam, A. S., & Mayhoub, A. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119449
BindingDB Entry 50016732: The Ascension of Targeted Covalent Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q23f4tpf
BindingDB (2017) · UC San Diego · doi:10.7270/q20g3n1w
BindingDB (2020) · UC San Diego · doi:10.7270/q2xs5z29
BindingDB (2017) · UC San Diego · doi:10.7270/q25t3ncc
BindingDB (2018) · UC San Diego · doi:10.7270/q2rf5x00
BindingDB (2020) · UC San Diego · doi:10.7270/q25x2cjz
BindingDB (2016) · UC San Diego · doi:10.7270/q2fn1513
BindingDB Entry 50047333: Recent progress on third generation covalent EGFR inhibitors.
BindingDB (2017) · UC San Diego · doi:10.7270/q2c24z9v
BindingDB Entry 50047985: Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a
BindingDB (2018) · UC San Diego · doi:10.7270/q2cn75vh
BindingDB (2020) · UC San Diego · doi:10.7270/q2hh6nmn
BindingDB Entry 50018884: Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.
BindingDB (2024) · UC San Diego · doi:10.7270/q2d50s68
BindingDB Entry 50015311: Discovery of highly potent and selective EGFR
BindingDB (2023) · UC San Diego · doi:10.7270/q2m330pb
BindingDB (2020) · UC San Diego · doi:10.7270/q2h70jf4
BindingDB (2017) · UC San Diego · doi:10.7270/q2ks6tdd
BindingDB (2020) · UC San Diego · doi:10.7270/q2wq0680
BindingDB Entry 50001688: Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
BindingDB (2020) · UC San Diego · doi:10.7270/q2zg6vs2
BindingDB Entry 50008580: Discovery of a potent dual ALK and EGFR T790M inhibitor.
BindingDB (2021) · UC San Diego · doi:10.7270/q2wh2tcg
Metadata
- Authors
- Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R. C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A. D., Harding, T. C., & Allen, A.
- Affiliations
- Vanderbilt University (US)
- Authors' Affiliations: 1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland
- Corresponding author
- Harding, Thomas C.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1404-1415
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4048995
- OpenAlex
- W2146418087
- Cited by
- 620
- References
- 43
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 29 · 2022: 32 · 2021: 41 · 2020: 51 · 2019: 44 · 2018: 61 · 2017: 87 · 2016: 92 · 2015: 86 · 2014: 44 · 2013: 3
- FWCI
- 62.72
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HHSN261200800001C)
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, HHSN261200800001E), U54CA143798, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- EGFR tyrosine kinase inhibitors, T790M mutation, acquired drug resistance, non-small cell lung cancer, irreversible kinase inhibitors, epithelial-mesenchymal transition, AKT inhibitors, on-target toxicity
- MeSH terms
- Acrylamides, Administration, Oral, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Screening Assays, Antitumor, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mice, Transgenic, Pyrimidines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mutant Proteins, Mice, HEK293 Cells, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
